TCGA-CQ-5330-01A-01R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- INTERFERON_ALPHA_RESPONSE+0.530
- MYOGENESIS+0.530
- INTERFERON_GAMMA_RESPONSE+0.450
- ALLOGRAFT_REJECTION+0.400
- ANGIOGENESIS+0.400
- HEDGEHOG_SIGNALING+0.350
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.360
- FATTY_ACID_METABOLISM-0.300
- MTORC1_SIGNALING-0.280
- PANCREAS_BETA_CELLS-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
- P53_PATHWAY-0.230
- PEROXISOME-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.220
- PI3K_AKT_MTOR_SIGNALING-0.210
- SPERMATOGENESIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.806 |
| 2 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.797 |
| 3 | SRR10900585 | — | — | 0.791 |
| 4 | TCGA-D6-6515-01A-21R-1873-07 | — | — | 0.774 |
| 5 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.772 |
| 6 | 20030032.TNBC | — | D | 0.770 |
| 7 | 20020022.TNBC | — | D | 0.764 |
| 8 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.762 |
| 9 | TCGA-XF-AAMT-01A-11R-A42T-07 | — | — | 0.761 |
| 10 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| MYOGENESIS | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |